Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

ARS Pharmaceuticals, Inc.

NASDAQ: SPRY · Life Sciences · 2 alerts · CIK 1671858

Share price
$3.59Close, Nov 16
Market cap
$361M
Shares outstanding
100.53MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All ARS Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:10 PM ET 10-Q
Financial Results

ARS Pharmaceuticals Q3 2026 Results: Net Loss of $35.6M, Loss Narrows

ARS Pharmaceuticals is focused on the commercialization of neffy, its intranasal epinephrine product, following recent regulatory approvals. The company reported 100,528,400 shares of common stock outstanding as of November 3, 2026, and is classified as a non-accelerated filer and smaller reporting company.

Key figure
Net loss $35.6M
4:04 PM ET 8-K
Financial Results

ARS Pharmaceuticals Financial Results

ARS Pharmaceuticals reported Q3 2026 financial results with total revenue of $37.7 million, driven by $33.4 million in U.S. net product revenue for neffy. The company achieved a 5% overall U.S. market share for neffy and reaffirmed its path to cash flow breakeven by year-end 2027.

Term
Q3 2026

“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each.”

Donn Casale, President and Chief Executive Officer

“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market.”

Meg Smith, Chief Commercial Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.